Search

Your search keyword '"Antibodies, Neutralizing isolation & purification"' showing total 293 results

Search Constraints

Start Over You searched for: Descriptor "Antibodies, Neutralizing isolation & purification" Remove constraint Descriptor: "Antibodies, Neutralizing isolation & purification"
293 results on '"Antibodies, Neutralizing isolation & purification"'

Search Results

1. Expression and characterization of scFv-6009FV in Pichia pastoris with improved ability to neutralize the neurotoxin Cn2 from Centruroides noxius.

2. Anti-idiotype isolation of a broad and potent influenza A virus-neutralizing human antibody.

3. Gold-silver alloy hollow nanoshells-based lateral flow immunoassay for colorimetric, photothermal, and SERS tri-mode detection of SARS-CoV-2 neutralizing antibody.

4. Protective anti-gB neutralizing antibodies targeting two vulnerable sites for EBV-cell membrane fusion.

5. Structural basis for ultrapotent antibody-mediated neutralization of human metapneumovirus.

6. Detection and quantification of antibody to SARS CoV 2 receptor binding domain provides enhanced sensitivity, specificity and utility.

7. Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants.

8. Enhancing neutralization of Plasmodium falciparum using a novel monoclonal antibody against the rhoptry-associated membrane antigen.

9. Neutralizing antibodies induced in immunized macaques recognize the CD4-binding site on an occluded-open HIV-1 envelope trimer.

10. Latex Microsphere-Based Bicolor Immunochromatography for Qualitative Detection of Neutralizing Antibody against SARS-CoV-2.

11. A cell-free high throughput assay for assessment of SARS-CoV-2 neutralizing antibodies.

12. RSV Vaccines, Finally Within Reach, Could Prevent Tens of Thousands of Yearly Deaths.

13. SARS-CoV-2 reactive and neutralizing antibodies discovered by single-cell sequencing of plasma cells and mammalian display.

14. Comparative performance of multiplex salivary and commercially available serologic assays to detect SARS-CoV-2 IgG and neutralization titers.

15. Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants.

16. Nanobodies as powerful pulmonary targeted biotherapeutics against SARS-CoV-2, pharmaceutical point of view.

17. Development of a Purified Viral Preparation for Studies of COVID-19 (SARS-CoV-2) Biology.

18. A competitive ligand-binding assay to detect neutralizing antibodies to a bispecific drug using a multiplex Meso Scale Discovery platform.

19. COVID-19 antibody donation using immunoadsorption: Report of two cases.

20. Broad betacoronavirus neutralization by a stem helix-specific human antibody.

21. A functional assay for serum detection of antibodies against SARS-CoV-2 nucleoprotein.

22. Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern.

23. Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac.

24. Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19.

25. Effective high-throughput isolation of fully human antibodies targeting infectious pathogens.

26. Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants.

27. Rapid and reliable hybridoma screening method that is suitable for production of functional structure-recognizing monoclonal antibody.

28. A human bispecific neutralization antibody against four serotypes of dengue virus.

29. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.

30. SARS-CoV-2 Serologic Assays in Control and Unknown Populations Demonstrate the Necessity of Virus Neutralization Testing.

31. Extremely potent human monoclonal antibodies from COVID-19 convalescent patients.

32. Expression and Purification of a PEDV-Neutralizing Antibody and Its Functional Verification.

33. SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface.

34. Correlation of SARS-CoV-2 Neutralizing Antibodies to an Automated Chemiluminescent Serological Immunoassay.

35. Isolation of Porcine Reproductive and Respiratory Syndrome Virus GP5-Specific, Neutralizing Monoclonal Antibodies From Hyperimmune Sows.

36. Effective virus-neutralizing activities in antisera from the first wave of survivors of severe COVID-19.

37. Early detection of neutralizing antibodies against SARS-CoV-2 in COVID-19 patients in Thailand.

38. Nanobodies mapped to cross-reactive and divergent epitopes on A(H7N9) influenza hemagglutinin using yeast display.

39. Decline and loss of anti-SARS-CoV-2 antibodies in kidney transplant recipients in the 6 months following SARS-CoV-2 infection.

40. Longitudinal SARS-CoV-2 seroconversion and functional heterogeneity in a pediatric dialysis unit.

41. Stereotypic neutralizing V H antibodies against SARS-CoV-2 spike protein receptor binding domain in patients with COVID-19 and healthy individuals.

42. Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial.

43. Potent mouse monoclonal antibodies that block SARS-CoV-2 infection.

44. Versatile and rapid microfluidics-assisted antibody discovery.

45. Micro-fusion inhibition tests: quantifying antibody neutralization of virus-mediated cell-cell fusion.

46. Autologous IgG antibodies block outgrowth of a substantial but variable fraction of viruses in the latent reservoir for HIV-1.

47. Evidence of exposure to SARS-CoV-2 in cats and dogs from households in Italy.

48. The development of neutralizing antibodies against SARS-CoV-2 and their common features.

49. Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms.

50. Comparison of the ELISA and ECL Assay for Vedolizumab Anti-drug Antibodies: Assessing the Impact on Pharmacokinetics and Safety Outcomes of the Phase 3 GEMINI Trials.

Catalog

Books, media, physical & digital resources